edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.
Kazia Therapeutics — 9 videos in collection
In this video, Kazia’s CEO, Dr James Garner, explains the background to this interesting product which has a novel brain penetrating action which potentially could give it a unique role in the chronic treatment of glioblastoma. He discusses the latest trial data and the further development of the product in 2020.
Get access to the very latest content matched to your personal investment style.